CXCR4: A Critical Player in Cancer, Immunity, and Therapeutic Innovation - Conigen Bioscience The CXCR4-CMP is stable and bioactive. It can be specifically and potently bound by CXCR4-specific antibody, and more importantly, it can bind to its ligand CXCL12 and HIV-1 envelope glycoprotein.

CXCR4, an emerging key therapeutic target. Conigen is developing an innovative #CXCR4 platform for conducting in vivo animal #immunization and in vitro #bioassays. This platform supports research in areas such as #receptorligandinteractions, #drugscreening, and #mechanisticstudies. bit.ly/3ONMzlL